• You're noticing early to moderate jawline or jowl softening
• Skin feels less "anchored" than it used to — especially at the midface
• You've been told you're "not quite ready" for filler but you know something has shifted
• You want to delay or complement a surgical conversation
• You have a darker skin tone and have been told energy treatments aren't safe for you
• You want a treatment backed by peer-reviewed histology, not just before-and-afters
• You have a busy schedule and cannot take downtime
• You've had Thermage or Ultherapy and want something with a more advanced mechanism

• Your primary concern is pigmentation, texture, or active acne (we have other tools for those)
• You have an active implanted electronic device (pacemaker, nerve stimulator)
• You're seeking results from advanced or severe laxity that warrants surgical evaluation
• You're pregnant or nursing
• You have an open wound or active skin infection in the treatment area
• You're looking for immediate, dramatic change in a single session with no commitment to skin health

Treatment - 60-70 minutes for a full face and neck. You'll feel warmth — deep, radiating warmth — with surface cooling delivered continuously. Most patients find this surprisingly comfortable. No numbing, no breaks needed.

Immediately After-Mild redness resolves within hours. No restrictions on activity, exercise, or sun exposure beyond standard post-treatment SPF. You leave looking like yourself — no swelling, no downtime.

Results Over Time-Immediate tissue contraction is subtle and real. Progressive collagen remodeling peaks at 3–6 months. Most patients see significant improvement after 1–2 sessions; a maintenance protocol can be customized annually.

In in-vivo studies, Cynosure Lutronic measured internal skin temperatures of 50°C, 60°C, and 70°C using ultrasound-guided fiber-optic imaging. Following the XERF treatment, histological analysis confirmed collagen remodeling.

Histological evidence from in-vivo porcine studies shows increased thickening and tightening of collagen bundles at multiple tissue depths, along with an observable upward pull in the fascia.

Histological analysis from multiple clinical studies confirms the XERF system delivers RF energy to the SMAS (Superficial Musculoaponeurotic System). The SMAS is a foundational tissue layer beneath the skin that plays a key role in lifting and tightening sagging skin and reducing the appearance of jowls.

This is one of the most common questions I get from patients who've done any research. Beginning around 2022–2023, a wave of reports — on social media, RealSelf, and eventually mainstream publications — described patients experiencing unexpected facial hollowing after Morpheus8 treatments. Volume loss at the temples, cheeks, and under-eye area. Faces that looked thinner, more skeletal, older in a different way than before.

Some of it was real. Some was swelling resolution that was misread as volume loss. Some was a result of providers running Morpheus8 at depths and energy levels appropriate for body contouring — not facial rejuvenation. The device can reach subcutaneous fat intentionally when set to do so. When those settings were applied to the face without the appropriate anatomical consideration, fat was affected. The concern is legitimate. It came from real patient experiences, not internet hysteria.

What that conversation did, which was both useful and problematic, was conflateRF microneedling with all RF devices. XERF is not Morpheus8. The delivery systems, the energy pathways, and the tissue targets are mechanistically distinct. This is the answer to why.

Why Morpheus8 can affect fat, and XERF cannot.

The Morpheus8 fat issue has a specific mechanical explanation. Morpheus8 is RF microneedling — it delivers radiofrequency energy through insulated needles that physically penetrate the skin and deposit energy near the needle tip at the selected depth. When those needles are set to their deeper settings (3.5–4 mm or beyond on certain tips), the tip reaches into or near the subcutaneous fat layer. RF energy deposited at that depth, at sufficient temperature, heats and can damage adipocytes — the fat cells.

This is not a bug in Morpheus8. It is a design feature when intentionally used for submental fat reduction or jowl contouring. The problem was practitioner error: using deep settings designed for body applications on thin facial tissue, in zones where the distance from skin surface to fat is very short — temples, under-eye, lateral cheek — without accounting for anatomy. The fat didn't melt randomly. It was heated by needles that were set to reach it.

RF MICRONEEDLING

Needles enter tissue. Energy deposits at tip depth.

Insulated microneedles physically penetrate dermis and, at deeper settings, the subcutaneous fat layer. RF energy is concentrated near the needle tip at the preset depth. At facial fat depths (1.5–4 mm in thin-skinned zones), fat cells are within range of that thermal deposit.

When depth exceeds the dermis in areas with thin subcutaneous fat, adipocytes receive sufficient heat to sustain thermal damage. Volume loss follows. This is mechanism-dependent, not operator error alone.

FAT IS REACHABLE — BY DESIGN, AND BY MISTAKE. XERF — SURFACE MONOPOLAR RF

Electrode sits on skin surface. Energy diffuses volumetrically.

No needles. No penetration. The active electrode rests on the skin surface; current travels volumetrically through tissue toward a return pad placed elsewhere on the body. Energy disperses as it passes through tissue layers — it does not concentrate at a specific depth the way a needle tip does.

By the time the RF field reaches subcutaneous fat, energy has diffused significantly. The thermal target is the dermis and fibrous septa — not fat cells. The built-in cryogen cooling actively protects the surface while deeper tissue reaches therapeutic temperature through resistance-based heating.

NO NEEDLE ENTRY. NO FOCAL FAT-DEPTH ENERGY DEPOSIT.

The histological evidence is direct on this point.

The XERF in vivo study published in 2025 (PMC12662868) explicitly examined adipocyte morphology as part of its histological analysis. The investigators assessed subcutaneous fat tissue at 7, 15, and 30 days post-treatment. The finding, stated directly in the paper: "preserved adipocyte morphology with no evidence of structural disruption." Complementary TUNEL assays — which detect apoptotic cell death — revealed no apoptotic cells in the subcutaneous adipocytes or fibrous components.2

This was not assumed or modeled. It was stained, examined under microscopy, and documented. Adipocytes were present, intact, and structurally undisturbed after XERF treatment that reached the fibrous septa level. The fat was there before. The fat was there after. The fibrous septa between the fat lobules were remodeled. The fat cells themselves were not.

"Preserved adipocyte morphology with no evidence of structural disruption" — PMC12662868, in vivo histological analysis of XERF, days 7, 15, and 30 post-treatment.PMC12662868 · IN VIVO HISTOLOGY · 2025Fat cells intact. TUNEL assay: zero apoptotic adipocytes.

Post-XERF histological specimens at 7, 15, and 30 days confirmed preserved subcutaneous adipocyte morphology throughout. No cell death, no structural disruption, no fat volume reduction. The thermal effect was confined to collagen and elastic fiber remodeling in the dermis and fibrous septa.

PMC12662868.Full text → CONTEXT — MORPHEUS8 FAT RISK · DOCUMENTED MECHANISMRF microneedling fat injury: needle depth + energy density at fat layer.

Morpheus8 fat loss reports are mechanistically consistent: deeper needle settings (3.5–4mm+) in thin facial zones deposit RF energy at or within the subcutaneous fat layer. At sufficient temperature and duration, adipocytes sustain thermal injury. This mechanism is absent in surface-applied monopolar RF.

Multiple documented case reports; Renovatio Clinic analysis, 2026.

So what does XERF actually do to the area above fat?

The fibrous septa — the connective tissue strands that run between fat lobules, anchoring skin to deeper structures — are what XERF remodels at depth. These are distinct from the adipocytes themselves. Think of the fat as the content and the fibrous septa as the structural scaffolding within it. XERF heats and tightens the scaffolding. The fat stays.

This is actually the correct target for facial laxity. The drooping and descent that characterizes midface aging is not primarily about fat loss — it's about the retaining ligaments and fibrous septa losing tensile strength and allowing fat compartments to migrate inferiorly. Tightening those septa without disturbing the fat they surround is precisely the intended effect. The histology confirms that is what happens.

What about the tightening effect — isn't that kind of a "slimming"?

Some patients notice their face looks slightly more defined after XERF. This is not fat loss — it's tissue reorganization. The fascial tightening and skin contraction from collagen remodeling can redistribute or elevate tissue in a way that reads as more defined. The mechanism is lifting, not reduction. Volume is maintained; position improves.

This is meaningfully different from the hollowing pattern reported with Morpheus8, which was characterized by temporal volume loss, under-eye hollowing, and a skeletonized appearance — the signature of actual fat cell destruction in thin-tissue zones. That pattern has not been documented with surface monopolar RF, and the histological evidence explains why it wouldn't be.

THE CLINICAL ANSWER

XERF can not melt your fat by the mechanism that caused Morpheus8 fat loss.Morpheus8's fat issue was caused by RF energy deposited at subcutaneous fat depth via penetrating microneedles. XERF delivers energy from the skin surface — no needles, no focal depth deposit, no ability to concentrate heat at the fat layer.

The 2025 in vivo histological study examined subcutaneous adipocytes specifically and confirmed preserved morphology with zero apoptotic cells at 7, 15, and 30 days. The fat that was there before treatment was there after. What changed was the fibrous septa between fat compartments — thicker, better organized, and under upward fascial pull. That's the result. Not reduction. Reorganization.

If you've been hesitant about RF treatments because of what you saw happen with Morpheus8, that hesitation was reasonable — and it applies to a different device with a different mechanism. XERF is not that device. Though new to the U.S this has been studied for years in Asian countries. That is also not to say the phenomenon can not happen.

WHY THIS QUESTION EXISTS

This one comes from plastic surgeons and is reasonable: if a device is marketing its ability to reach the SMAS — the same layer addressed in a surgical facelift — the logical follow-up is, what happens to that layer when you heat it from the outside? Can you damage it? Scar it? Compromise future surgical outcomes?

The mechanism is the answer.

XERF does not create focal coagulation points. It delivers volumetric heat — a broad, graduated thermal field that diffuses through tissue as it travels from the surface electrode through the body to the return pad. The 2 MHz frequency reaches the SMAS because lower RF frequencies penetrate deeper, but that energy is distributed across a 20 × 30 mm treatment field per shot, not concentrated into a 1–2 mm column the way focused ultrasound is.

The thermal profile at the SMAS level, by the time energy has traveled through the dermis and subcutaneous tissue, is a diffuse warming — measured in vivo at 50–70°C at target depth, with the critical variable being that these temperatures are reached at the collagen and fibrous septa level, not concentrated into a coagulation point at a fascial plane. The effect is controlled contracture and remodeling of that tissue. Not ablation. Not coagulation zones. Not structural disruption.

The distinction between volumetric RF heating and focal ultrasound coagulation is not semantic. It is the entire reason one can injure a nerve and the other has not been shown to.

What the histology actually shows at the SMAS level.

The in vivo porcine study published in Skin Research & Technology (2024) examined tissue at multiple timepoints after XERF treatment. The findings at the deep fascial layer were: thickening and upward pull of the fascia — not necrosis, not disorganization, not structural disruption.1 This is the histological signature of contracture and remodeling, not injury.

The companion computational modeling and histologic analysis (PMC12662868, 2025) specifically examined the subcutaneous fibrous septa and deep fascial layers with Verhoeff-van Gieson staining. At 7, 15, and 30 days post-treatment, the findings were: increased clumped elastic fibers at day 7, progressing to numerous thick and elongated elastic fibers at days 15 and 30 — a remodeling sequence, not a damage sequence.2Adipocyte morphology was preserved throughout with no evidence of structural disruption and no apoptotic fat cells on TUNEL assay.

SKIN RES TECHNOL · 2024 · DOI: 10.1111/SRT.13821Fascial thickening and upward pull confirmed histologically — no disruption.

Dual-frequency XERF produced thickened and shortened collagen bundles and measurably thickened deep fascial layers within 6 hours. The tissue architecture was reorganized and strengthened — not coagulated or destroyed.

Hong J, Ryu HG, et al. Lutronic Corp, Goyang, South Korea.PubMed →PMC12662868 · 2025 — IN VIVO HISTOLOGYElastic fiber regeneration at fibrous septa with preserved adipocyte morphology throughout.

Verhoeff-van Gieson staining at days 7, 15, and 30 showed progressive elastic fiber thickening and elongation extending into the dermo-subcutaneous junction and subcutaneous fibrous septa. No fat cell disruption. No apoptotic cells on TUNEL assay.

PMC12662868. Cynosure Lutronic Inc., Goyang, South Korea.Full text →

On the question of future surgical viability.

This is the question plastic surgeons are specifically asking: if you treat the SMAS with RF, are you creating scar tissue that complicates a future facelift dissection? The histological answer from the available studies is no — the tissue response is reorganization and strengthening of existing collagen and elastic fiber architecture, not fibrosis. The SMAS after XERF treatment is thicker and better organized, not scarred.

The parallel question was raised about Ultherapy and surgical planning. The clinical consensus that emerged was that Ultherapy did not preclude surgery when performed appropriately. XERF's mechanism — volumetric RF that strengthens rather than ablates — is, if anything, a lower-disruption profile than focused ultrasound at the same depth. A surgeon operating on a patient who has had XERF is encountering firmer, better-organized fascial tissue, not fibrous scar planes.

The real risk is provider calibration — not mechanism.

The honest version of this conversation: the SMAS risk with energy devices is not theoretical. It happened with Ultherapy when providers used incorrect transducer depths, excessive energy, or failed to account for thin-tissue anatomy. The structural damage in those cases came from concentrated focal energy deposited at the wrong depth or in the wrong tissue — not from the concept of reaching the SMAS itself.

XERF's risk mitigation is built into the hardware: Accurate Impedance Feedback adjusts energy delivery in real time, the three depth modes prevent inadvertent over-penetration at shallow anatomical sites, and the non-focal delivery mechanism means there is no single column of high-intensity energy being aimed at a fascial plane. Provider calibration still matters — it always does — but the mechanism is fundamentally less prone to the focal injury pattern that generated legitimate concern about focused ultrasound.

XERF reaching the SMAS is not the same as XERF injuring the SMAS. The mechanism is volumetric RF heating — a diffuse thermal field that induces contracture and remodeling across a broad area. The histological outcome at the SMAS level is thickening and fascial tightening, not coagulation zones, not fibrosis, not structural disruption. The injury profile that made plastic surgeons wary of Ultherapy was a product of focal ultrasound energy delivery — a fundamentally different physics than what's happening here. The evidence available does not support structural injury concern with XERF at clinically appropriate settings.

That does not make this a no-thought treatment. Anatomy-informed calibration, depth mode selection, and patient selection still matter. They always do. But the mechanism is not where the risk lives.